These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 17996858

  • 1. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.
    Damsten MC, van Vugt-Lussenburg BM, Zeldenthuis T, de Vlieger JS, Commandeur JN, Vermeulen NP.
    Chem Biol Interact; 2008 Jan 10; 171(1):96-107. PubMed ID: 17996858
    [Abstract] [Full Text] [Related]

  • 2. The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities.
    Yun CH, Kim KH, Kim DH, Jung HC, Pan JG.
    Trends Biotechnol; 2007 Jul 10; 25(7):289-98. PubMed ID: 17532492
    [Abstract] [Full Text] [Related]

  • 3. Application of CYP102A1M11H as a tool for the generation of protein adducts of reactive drug metabolites.
    Boerma JS, Vermeulen NP, Commandeur JN.
    Chem Res Toxicol; 2011 Aug 15; 24(8):1263-74. PubMed ID: 21639118
    [Abstract] [Full Text] [Related]

  • 4. Role of residue 87 in the activity and regioselectivity of clozapine metabolism by drug-metabolizing CYP102A1 M11H: application for structural characterization of clozapine GSH conjugates.
    Rea V, Dragovic S, Boerma JS, de Kanter FJ, Vermeulen NP, Commandeur JN.
    Drug Metab Dispos; 2011 Dec 15; 39(12):2411-20. PubMed ID: 21890734
    [Abstract] [Full Text] [Related]

  • 5. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3.
    Kim DH, Kim KH, Kim DH, Liu KH, Jung HC, Pan JG, Yun CH.
    Drug Metab Dispos; 2008 Nov 15; 36(11):2166-70. PubMed ID: 18669587
    [Abstract] [Full Text] [Related]

  • 6. Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis.
    van Vugt-Lussenburg BM, Stjernschantz E, Lastdrager J, Oostenbrink C, Vermeulen NP, Commandeur JN.
    J Med Chem; 2007 Feb 08; 50(3):455-61. PubMed ID: 17266197
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of alkoxyresorufins as fluorescent substrates for cytochrome P450 BM3 and site-directed mutants.
    Lussenburg BM, Babel LC, Vermeulen NP, Commandeur JN.
    Anal Biochem; 2005 Jun 01; 341(1):148-55. PubMed ID: 15866539
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficient screening of cytochrome P450 BM3 mutants for their metabolic activity and diversity toward a wide set of drug-like molecules in chemical space.
    Reinen J, van Leeuwen JS, Li Y, Sun L, Grootenhuis PD, Decker CJ, Saunders J, Vermeulen NP, Commandeur JN.
    Drug Metab Dispos; 2011 Sep 01; 39(9):1568-76. PubMed ID: 21673132
    [Abstract] [Full Text] [Related]

  • 12. Screening and identification of GSH-trapped reactive metabolites using hybrid triple quadruple linear ion trap mass spectrometry.
    Zheng J, Ma L, Xin B, Olah T, Humphreys WG, Zhu M.
    Chem Res Toxicol; 2007 May 01; 20(5):757-66. PubMed ID: 17402749
    [Abstract] [Full Text] [Related]

  • 13. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
    Huang WC, Westlake AC, Maréchal JD, Joyce MG, Moody PC, Roberts GC.
    J Mol Biol; 2007 Oct 26; 373(3):633-51. PubMed ID: 17868686
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The dimeric form of flavocytochrome P450 BM3 is catalytically functional as a fatty acid hydroxylase.
    Neeli R, Girvan HM, Lawrence A, Warren MJ, Leys D, Scrutton NS, Munro AW.
    FEBS Lett; 2005 Oct 24; 579(25):5582-8. PubMed ID: 16214136
    [Abstract] [Full Text] [Related]

  • 17. A highly active single-mutation variant of P450BM3 (CYP102A1).
    Whitehouse CJ, Bell SG, Yang W, Yorke JA, Blanford CF, Strong AJ, Morse EJ, Bartlam M, Rao Z, Wong LL.
    Chembiochem; 2009 Jul 06; 10(10):1654-6. PubMed ID: 19492389
    [Abstract] [Full Text] [Related]

  • 18. Trimethoprim: novel reactive intermediates and bioactivation pathways by cytochrome p450s.
    Damsten MC, de Vlieger JS, Niessen WM, Irth H, Vermeulen NP, Commandeur JN.
    Chem Res Toxicol; 2008 Nov 06; 21(11):2181-7. PubMed ID: 18816075
    [Abstract] [Full Text] [Related]

  • 19. Laboratory evolution of P450 BM3 for mediated electron transfer yielding an activity-improved and reductase-independent variant.
    Nazor J, Dannenmann S, Adjei RO, Fordjour YB, Ghampson IT, Blanusa M, Roccatano D, Schwaneberg U.
    Protein Eng Des Sel; 2008 Jan 06; 21(1):29-35. PubMed ID: 18093991
    [Abstract] [Full Text] [Related]

  • 20. Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium.
    Gustafsson MC, Roitel O, Marshall KR, Noble MA, Chapman SK, Pessegueiro A, Fulco AJ, Cheesman MR, von Wachenfeldt C, Munro AW.
    Biochemistry; 2004 May 11; 43(18):5474-87. PubMed ID: 15122913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.